References
- Choudhary OP, Choudhary P, Singh I. India’s COVID-19 vaccination drive: key challenges and resolutions. Lancet Infect Dis. 2021;21(11):1483–84. doi:10.1016/S1473-3099(21)00567-3.
- Choudhary OP, Priyanka SI, Rodriguez-Morales AJ. Second wave of COVID-19 in India: dissection of the causes and lessons learnt. Travel Med Infect Dis. 2021;43:102126. doi:10.1016/j.tmaid.2021.102126.
- Choudhary OP, Priyanka, Singh I, Mohammed TA, Rodriguez-Morales AJ. Fake COVID-19 vaccines: scams hampering the vaccination drive in India and possibly other countries. Hum Vaccines Immunother. 2021. doi:10.1080/21645515.2021.1960770.
- Priyanka COP, Singh I, Patra G. Aerosol transmission of SARS-CoV-2: the unresolved paradox. Travel Med Infect Dis. 2020;37:101869. doi:10.1016/j.tmaid.2020.101869.
- Ahmed JQ, Tayib GA, Mohamed T. SARS-CoV-2 mutation hotspots incidence in different geographic regions. Microb Biosyst. 2020;5(2):1–8. doi:10.21608/MB.2020.46676.1026.
- Shaw RH, Stuart A, Greenland M, Liu X, Van-Tam JSN, Snape MD. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397(10289):2043–46. doi:10.1016/S0140-6736(21)01115-6.
- He Q, Mao Q, An C, Zhang J, Gao F, Bian L, Li C, Liang Z, Xu M, Wang J. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021;10(1):629–37. doi:10.1080/22221751.2021.1902245.
- Schmidt T, Klemis V, David Schub D, Janine Mihm J, Franziska Hielscher F, Stefanie Marx S, Amina Abu-Omar A, Schneitler S, Becker SL, Gärtner BC, et al. Immunogenicity and reactogenicity of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens. medRxiv; 2021. doi:10.1101/2021.06.13.21258859.
- World Health Organization. The Oxford/AstraZeneca COVID-19 vaccine: what you need to know. 2021 [accessed 2021 Sep 28]. https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know#:~:text=How%20efficacious%20is%20the%20vaccine,associated%20with%20greater%20vaccine%20efficacy.
- World Health Organization. The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: what you need to know. 2021 [accessed 2021 Sep 28]. https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19–vaccine#:~:text=How%20efficacious%20is%20the%20vaccine,SARS%2DCoV%2D2%20infection.
- World Health Organization. The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know. 2021 [accessed 2021 Sep 28]. https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know.
- Frederiksen LSF, Zhang Y, Foged C, Thakur A. The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunisation strategies. Front Immunol. 2020;11:1817. doi:10.3389/fimmu.2020.01817.
- Daou A. COVID-19 vaccination: from interesting agent to the patient. Vaccines. 2021;9(2):120. doi:10.1038/nm.2972.
- García-Montero C, Fraile-Martínez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, Gómez-Lahoz AM, Guijarro LG, García-Honduvilla N, Asúnsolo A, Bujan J, et al. An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines. 2021;9(5):433. doi:10.3390/vaccines9050433.
- Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Eng J Med. 2021;384(22):2092–101. doi:10.1056/NEJMoa2104840.
- Tenbusch M, Schumacher S, Vogel E, Priller A, Held J, Steininger P, Beileke S, Irrgang P, Brockhoff R, Salmanton-García J, et al. Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect Dis. 2021;21(9):1212–13. doi:10.1016/S1473-3099(21)00420-5.
- Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, Campins M, Portolés A, González-Pérez M, García Morales TG, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398:121–30. doi:10.1016/S0140-6736(21)01420-3.
- MacNeil JR, Su JR, Broder KR, Guh AY, Gargano JW, Wallace M, Hadler SC, Scobie HM, Blain AE, Moulia D, et al. Updated recommendations from the advisory committee on immunisation practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients- United States, April 2021. Morb Mortal Wkly Rep. 2021;70(17):651–56. doi:10.15585/MMWR.MM7017E4.
- Normark J, Vikström L, Gwon YD, Persson IL, Edin A, Björsell T, Dernstedt A, Christ W, Tevell S, Evander M, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N Eng J Med. 2021;385(11):1049–51. doi:10.1056/NEJMc2110716.
- Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. New Eng J Med. 2021;384:1885–98. doi:10.1056/NEJMoa2102214.
- The Hindu. Amid vaccine shortage, Bhutan for mixing doses. [accessed 2021 Aug 21]. https://www.thehindu.com/news/international/amid-vaccine-shortage-bhutan-for-mixing-doses/article34955317.ece.
- Khan S, Dhama K. India’s role in COVID-19 vaccine diplomacy. J Travel Med. 2021;taab064. doi:10.1093/jtm/taab064.
- Kant R, Dwivedi G, Zaman K, Sahay RR, Sapkal G, Kaushal H, Nyayanit D, Yadav P, Deshpande G, Singh R, et al. Serendipitous COVID-19 vaccine-mix in Uttar Pradesh, India: safety and immunogenicity assessment of a heterologous regime. medRxiv; 2021. doi:10.1101/2021.08.06.21261716.